$-0.09 EPS Expected for IMV Inc. (IMV)

October 6, 2018 - By Robert Shackelford

IMV Inc. (TSE:IMV) Logo

Analysts expect IMV Inc. (TSE:IMV) to report $-0.09 EPS on November, 8.After having $-0.12 EPS previously, IMV Inc.’s analysts see -25.00 % EPS growth. The stock increased 0.70% or $0.05 during the last trading session, reaching $7.22. About 22,804 shares traded. IMV Inc. (TSE:IMV) has 0.00% since October 7, 2017 and is . It has underperformed by 15.62% the S&P500.

Immunovaccine Inc., a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company has market cap of $324.13 million. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It currently has negative earnings. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: